Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada specifies timelines for inspections in new guidance

This article was originally published in The Gold Sheet

Executive Summary

Health Canada has issued a final guidance outlining its policy on the scheduling of inspections. The guidance is called "GMP Inspection Policy for Canadian Drug Establishments" and requires that new establishments should be ready for an inspection when submitting their application for an establishment license (EL). The agency will perform an initial inspection within three months of receiving a request for an EL. The agency warns that if establishments are not prepared for an initial inspection when contacted by the inspectorate, their application will be withdrawn. The new policy went into effect for all inspections scheduled after Jan. 31. The guidance notes that fabricators, packagers, labelers and testing laboratories will be inspected every 24 months, while importers, distributors and wholesalers will be inspected every 36 months

You may also be interested in...



Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes

Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.

UsernamePublicRestriction

Register

PS000242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel